Research and Development

We are currently involved in new approaches to providing affordable, safe, and effective CAR T cells therapy, thus fostering cheaper cost.

1.LYSINE BIOTECH development of 2nd generation of CAR T cells & Lenti Virus Vector

To make a new approach to custom design provide affordable, safe, and effective Autologous huanti-CAR19 T cells Therapy

1.1 LYSINE BIOTECH Example design for a LysCAR19 T cell therapy with signal peptides, separate co-stimulators, and CD3ζ:

- Signal peptide: CD19-targeting signal peptide

- Linker: Gly-Ser linker

- Co-stimulator 1: CD27

- Co-stimulator 2: 4-1BB

- CD3ζ: Optimized CD3ζ domain

- ScFv regions: CD19 targeting ScFv regions

- Hinge and transmembrane regions: Optimized hinge and transmembrane regions

- CAR endodomain: Designed to incorporate separate co-stimulators and CD3ζ

1.2 LYSINE BIOTECH Novel binders construct huanti-CAR19 cation-pi interaction improved binding affinity, specificity, and therapeutic efficacy

The CAR ScFv heavy and light chain variable fragment region contains aromatic residues e.g., phenylalanine (Phe, F), tyrosine (Tyr, Y), or tryptophan (Trp, W). that participate in cation-pi interactions with positively charged residues e.g., lysine (Lys, K) or arginine (Arg, R) on the target of the CD19 antigen

The cation-pi interaction helps stabilize the CAR ScFv region binding to the target CD19 antigen increasing the binding affinity, specificity, and therapeutic efficacy.

1.3 LYSINE BIOTECH development of Lentiviral Envelope, 2nd Packaging Plasmids transfer plasmids for CAR T Cell Therapy

To make a new approach to custom design Gag, Pol, Rev, VSV-G and Tat 2nd generation transfer plasmids and Gag & Pol; can be used with a plasmid encoding Rev.

1.4.Lysine Biotech Product: Development of Commercial Novel anti-huCAR19T-CD27/41-BB-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety

Phase 1: Establishing proof of concept (POC) for Lenti Virus Vector and CAR-T Cell

Phase 2: Adherent 293T cells to establish the Master Cell Bank (MCB)

Phase 3: Pre-Clinical Trial (PCT) Efficacy and Safety

Phase 4: Plasmid DNA GMP Production

Phase 5: Lentiviral GMP Production

Phase 6: CAR-T Cell GMP Manufacturing

Phase 7: Clinical Partnership

Phase 8: Clinical Trial (CT)

Phase 9: Business Strategy

Phase 10: Commercial Manufacturing Collaboration

Read More About Products R&D Pipline

3.Publications

I).Mayakrishnan Vijayakumar, BalakarthikeyanJanani, PriyaKannappan, Senthil Renganathan*, SameerAl-Ghamdi, Mohammed Alsaidan, Mohamed AAbdelaziz, Abubucker Peer Mohideen, Mohammad Shahid, Thiyagarajan Ramesh, 2021.In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies Saudi Journal of Biological Sciences. Oct.29-2021. doi: 10.1016/j.sjbs.2021.10.060.

II).Renganathan Senthil*, Manokaran Sakthivel, Singaravelu Usha, 2021. Structure-based drug design of peroxisome proliferator-activated receptor gamma inhibitors: ferulic acid and derivatives. J Biomol Struct Dyn. 39(4):1295-1311.doi: 10.1080/07391102.2020.1740790.

III).Konda Mani Saravanan, Haiping Zhang, Renganathan Senthil*, Kevin Kumar Vijayakumar, Vignesh Sounderrajan, Yanjie Wei, Harshavardhan Shakila, 2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. J Biomol Struct Dyn. 1-9.doi: 10.1080/07391102.2020.1834457.

IV).Mahendrarajan Venkatramanan, Pitchaipillai Sankar Ganesh, Renganathan Senthil*, Jeyachandran Akshay, Arumugam Veera Ravi, Kulanthaivel Langeswaran, Jamuna Vadivelu, Samuthira Nagarajan, Kaliaperumal Rajendran, Esaki Muthu Shankar, 2020. Inhibition of Quorum Sensing and Biofilm Formation in Chromobacterium violaceum by Fruit Extracts of Passiflora edulis. ACS Omega.5(40):25605-25616.doi: 10.1021/acsomega.0c02483.

V).Subrata Pramanik, Manisha Thaker, Ananda Gopu Perumal*, Rajasekaran Ekambaram, Naresh Poondla, Markus Schmidt, Pok‐Son Kim, Arne Kutzner, Klaus Heese, 2020. Proteomic Atomics Reveals a Distinctive Uracil‐5‐Methyltransferase. Molecular Informatics. Vol. 39, Issue 5,doi:10.1002/minf.201900135 .